Publications
Access to the model
The IQVIA CORE Diabetes Model team and other users regularly publish articles based on the IQVIA CORE Diabetes Model and presents in conferences such as ISPOR, the European Diabetes Association Annual Meeting or the American Diabetes Association Congress.
Articles
Titles / Authors |
Journal |
Year |
Read it |
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis |
Journal of Comparative Effectiveness Research |
2024 |
 |
Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States |
Journal of Managed Care & Specialty Pharmacy |
2023 |
 |
Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge |
Medical Decision Making |
2022 |
 |
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark |
Diabetes Therapy |
2022 |
 |
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark |
Journal of Comparative Effectiveness Research |
2022 |
 |
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease |
Diabetes Therapy |
2021 |
 |
Cost-Effectiveness of the FreeStyle Libre® System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden |
Diabetes Therapy |
2021 |
 |
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China |
Journal of Comparative Effectiveness Research |
2021 |
 |
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy |
Diabetes Therapy |
2021 |
 |
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China |
Cost Effectiveness and Resource Allocation |
2021 |
 |
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge |
Value in Health |
2020 |
 |
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes |
Journal of Comparative Effectiveness Research |
2020 |
 |
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK |
Diabetes Therapy |
2020 |
 |
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood |
Pharmacoeconomics |
2019 |
 |
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease |
Diabetes Therapy |
2019 |
 |
Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach |
Value in Health Regional Issue |
2019 |
 |
Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis |
Cost Effectiveness and Resource Allocation |
2019 |
 |
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge |
Value in Health |
2018 |
 |
Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden |
Eur Endocrinol |
2018 |
 |
The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (Fonda S, Graham C, Munakata J, Powers J, Price D, Vigersky R) |
Journal of diabetes science and technology |
2016 |
 |
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus (Henriksson M, Jindal R, Sternhufvud C, Bergenheim K, Sörstadius E, Willis M.) |
Pharmacoeconomics |
2016 |
 |
Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand (Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S) |
Applied Health Economics and Health Policy |
2016 |
 |
Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes (Peters J, Anderson R, Hye C) |
BMJ Open |
2016 |
 |
Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective (Roze S, Smith-Palmer J, Valentine W, Cook M, Jethwa M, de Portud S, Pickup J) |
Journal of Medical Ethics |
2016 |
 |
Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. (Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer B, Reznik Y, de Valk HW.) |
J Med Econ |
2016 |
 |
Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. (Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H.) |
Diabetes Technol Ther |
2016 |
 |
Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. (Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, de Portu S, Pickup JC.) |
J Med Econ |
2016 |
 |
Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. (Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ. ) |
J Med Econ |
2016 |
 |
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives (Deng W, Qui S, Yang G, Chen B) |
Journal of Therapeutics and Clinical Risk Management |
2015 |
 |
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation. (Evans M, McEwan P, Foos V.) |
Journal of Medical Economics |
2015 |
 |
Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy (Gordon J, Evans M, Puelles J, McEwan P) |
Diabetes Therapy |
2015 |
 |
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway (Huetson P, Palmer J, Levorsen J, Fournier M, Germe M, McLeod E) |
Journal of Medical Economics |
2015 |
 |
A Health Economic Evaluation of the Edge Study Using the Ims Core Diabetes Model (Lamotte M, Foos V, McEwan P, Paldanius P) |
Value in Health |
2015 |
 |
Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. (Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM.) |
Diabetes Res Clin Pract. |
2015 |
 |
Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review. (Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. ) |
Diabetic Medicine |
2015 |
 |
Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. (Goh SY, Tan SC, Lim LC, Chua B, Hunt B.) |
Journal of Diabetology |
2015 |
 |
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. (Hunt B, Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, Valentine WJ.) |
Value in Health Regional Issues |
2015 |
 |
Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. (Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J.) |
Diabetic Medicine |
2015 |
 |
Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. (Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ.) |
Diabetes Therapy |
2015 |
 |
Validation of the IMS CORE Diabetes Model. (McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D.) |
Value in Health |
2014 |
 |
Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. (Giorda CB, Nicolucci A, Pellegrini F, Kristiansen CK, Hunt B, Valentine WJ, Vespasiani G.) |
Diabetic Medicine |
2014 |
 |
Cost Effectiveness Analysis of Flash Glucose Monitoring for Type 2 Diabetes Patients Receiving Insulin Treatment In The Uk (Li H, Bilir S, Donga, Samiian P, Munakata J) |
Value in Health |
2014 |
 |
The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain. (Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.) |
J Med Econ |
2013 |
 |
Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. (Ericsson Å, Pollock RF, Hunt B, Valentine WJ.) |
Journal of Medical Economics |
2013 |
 |
Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. (Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. ) |
Diabetes Therapy |
2013 |
 |
Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. (Pollock RF, Muduma G, Valentine WJ. ) |
Diabetes, Obesity and Metabolism |
2013 |
 |
Correlating Cost Effectiveness Output with Patient Level Data Input Via the IMS Core Diabetes Model (CDM) (Lamotte M, Foos V, McEwan P, Palmer J) |
Value in Health |
2013 |
 |
Validation Of The Ukpds Outcomes Equations Using The Cardiff Type-2 Diabetes Model (McEwan P) |
Value in Health |
2013 |
 |
Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes (McEwan P, Foos V, Palmer J, Lamotte M, Grant D) |
Value in Health |
2013 |
 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. (Davies MJ, Chubb BD, Smith IC, Valentine WJ) |
Diabet Med |
2012 |
 |
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. (Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA) |
|
2012 |
 |
Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. (Kamble S, Schulman KA, Reed SD) |
Value Health |
2012 |
 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. (Lee WC, Samyshkin Y, Langer J, Palmer JL) |
J Med Econ |
2012 |
 |
A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. (Pollock RF, Curtis BH, Valentine WJ) |
J Med Econ |
2012 |
 |
A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. (Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ) |
Adv Ther |
2012 |
 |
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. (Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A) |
J Med Econ |
2012 |
 |
Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. (Smith-Palmer J, Fajardo-Montanana C, Pollock RF, Ericsson A, Valentine WJ) |
J Med Econ |
2012 |
 |
Cost-effectiveness of biphasic insulin aspart 30 vs. human premix insulin in type 2 diabetes from the payer's perspective in Bulgaria. (Valov V, Palmer J, Czech M, Savova A, Petrova G) |
Biotechnology & Biotechnological Equipment |
2012 |
 |
Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. (Yang L, Christensen T, Sun F, Chang J) |
Value Health |
2012 |
 |
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK (Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, et al) |
J Med Econ |
2011 |
 |
Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. (Goodall G, Costi M, Timlin L, Reviriego J, Sacristan JA, Smith-Palmer J, et al) |
Endocrinol Nutr |
2011 |
 |
Modelling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. (Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J) |
|
2011 |
 |
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. (Lee WC, Conner C, Hammer M) |
Curr Med Res Opin |
2011 |
 |
Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results? (Szmurlo D, Schubert A, Kostrzewska K, Rys P, Skrzekowska-Baran I) |
Pol Arch Med Wewn |
2011 |
 |
Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. (Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH) |
Scand J Public Health |
2011 |
 |
Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. (Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M) |
Clin Ther |
2011 |
 |
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. (Lee WC, Conner C, Hammer M) |
Clin Ther |
2010 |
 |
Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes. (Norgaard K, Sohlberg A, Goodall G) |
Ugeskr Laeger |
2010 |
 |
Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. (Palmer JL, Knudsen MS, Aagren M, Thomsen TL) |
J Med Econ |
2010 |
 |
Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. (Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J) |
Adv Ther |
2010 |
 |
Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. (Pollock RF, Valentine WJ, Goodall G, Brandle M) |
Swiss Med Wkly |
2010 |
 |
Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. (Smith-Palmer J, Curtis BH, Boye KS, Goodall G, Pillemer SR) |
Diabet Med |
2010 |
 |
Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. (Tunis SL, Minshall ME) |
Curr Med Res Opin |
2010 |
 |
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. (Tunis SL, Willis WD, Foos V) |
Curr Med Res Opin |
2010 |
 |
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. (Tunis SL, Sauriol L, Minshall ME) |
Appl Health Econ Health Policy |
2010 |
 |
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. (Brandle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ) |
Int J Clin Pharmacol Ther |
2009 |
 |
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. (Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ) |
Swiss Med Wkly |
2009 |
 |
Cost-effectiveness of insulin analogues for diabetes mellitus. (Cameron CG, Bennett HA) |
CMAJ |
2009 |
 |
Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. (Fonseca VA, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, et al) |
Diabetes Care |
2009 |
 |
The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. (Goodall G, Sarpong EM, Hayes C, Valentine WJ) |
BMC Endocr Disord |
2009 |
 |
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. (Gschwend MH, Aagren M, Valentine WJ) |
J Med Econ |
2009 |
 |
Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients. (Ikramuddin S, Klingman D, Swan T, Minshall ME) |
Am J Manag Care |
2009 |
 |
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. (Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ) |
Value Health |
2009 |
 |
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. (Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G) |
Diabetes Obes Metab |
2009 |
 |
An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. (Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ) |
Diabet Med |
2009 |
 |
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. (Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ) |
Cost Eff Resour Alloc |
2009 |
 |
Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. (St Charles ME, Sadri H, Minshall ME, Tunis SL) |
Clin Ther |
2009 |
 |
A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. (St Charles M, Lynch P, Graham C, Minshall ME) |
Value Health |
2009 |
 |
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. (St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL) |
Curr Med Res Opin |
2009 |
 |
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. (Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L) |
Cardiovasc Diabetol |
2009 |
 |
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. (Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L) |
Pharmacotherapy |
2009 |
 |
A cost-effectiveness analysis to illustrate the impact of cost definitions on results, interpretations and comparability of pharmacoeconomic studies in the US. (Tunis SL) |
Pharmacoeconomics |
2009 |
 |
Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modelling analysis. (Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, et al) |
Curr Med Res Opin |
2009 |
 |
Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. (Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C) |
Value Health |
2009 |
 |
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. (Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, et al) |
J Med Econ |
2008 |
 |
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. (Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, et al) |
Value Health |
2008 |
 |
Complication reducing effect of the information technology-based diabetes management system on subjects with type 2 diabetes. (Cho JH, Lee JH, Oh JA, Kang MJ, Choi YH, Kwon HS, et al) |
J Diabetes Sci Technol |
2008 |
 |
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. (Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, et al) |
Int J Clin Pract |
2008 |
 |
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. (Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ) |
Value Health |
2008 |
 |
Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark. (Palmer AJ, Lammert M, Hermansen K) |
Ugeskr Laeger |
2008 |
 |
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. (Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, et al) |
Curr Med Res Opin |
2008 |
 |
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. (Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al) |
Adv Ther |
2008 |
 |
Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance-«) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. (Ray JA, Huet D, Valentine WJ, Palmer AJ, Cugnardey N, Renaudin C) |
The British Journal of Diabetes & Vascular Disease |
2008 |
 |
Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states. (Tunis SL, Minshall ME) |
Am J Manag Care |
2008 |
 |
The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients. (Tunis SL, Minshall ME) |
Diabetes Technol Ther |
2008 |
 |
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. (Tunis SL, Minshall ME, St CM, Pandya BJ, Baran RW) |
Curr Med Res Opin |
2008 |
 |
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. (Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K) |
Adv Ther |
2008 |
 |
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. (Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ) |
Pharmacoeconomics |
2007 |
 |
Cost-effectiveness of diabetes case management for low-income populations. (Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, et al) |
Health Serv Res |
2007 |
 |
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. (Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, et al) |
Curr Med Res Opin |
2007 |
 |
Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain. (Pinol C, Roze S, Valentine W, Evers T) |
Gac Sanit |
2007 |
 |
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. (Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, et al) |
Curr Med Res Opin |
2007 |
 |
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. (Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, et al) |
Diabetes Obes Metab |
2007 |
 |
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modelling study of cost-effectiveness in the United States. (Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer A) |
Adv Ther |
2007 |
 |
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. (Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, et al) |
Diabet Med |
2007 |
 |
Cost-utility analysis of insulin pumps compared to multiple daily doses of insulin in patients with type 1 diabetes mellitus in Spain. (Conget D, I, Serrano CD, Rodriguez Barrios JM, Levy M, I, Castell AC, Roze S) |
Rev Esp Salud Publica |
2006 |
 |
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. (Palmer AJ, Dinneen S, Gavin JR, III, Gray A, Herman WH, Karter AJ) |
Curr Med Res Opin |
2006 |
 |
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. (Roze S, Valentine WJ, Evers T, Palmer AJ) |
Curr Med Res Opin |
2006 |
 |
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. (Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, et al) |
Adv Ther |
2006 |
 |
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. (Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S) |
Int J Clin Pract |
2006 |
 |
Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. (Watkins JB, Minshall ME, Sullivan SD) |
J Manag Care Pharm |
2006 |
 |
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. (Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, Ray J, et al) |
Clin Ther |
2005 |
 |
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. (Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ) |
Diabet Med |
2005 |
 |
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. (Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S) |
Curr Med Res Opin |
2005 |
 |
The CORE Diabetes Model. (Brandle M, Herman WH) |
Curr Med Res Opin |
2004 |
 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. (Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, et al) |
Curr Med Res Opin |
2004 |
 |
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, et al) |
Curr Med Res Opin |
2004 |
 |
Validation of the CORE Diabetes Model against epidemiological and clinical studies. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al) |
Curr Med Res Opin |
2004 |
 |
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, et al) |
Curr Med Res Opin |
2004 |
 |
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al) |
Curr Med Res Opin |
2004 |
 |
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, et al) |
Curr Med Res Opin |
2004 |
 |
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. (Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU) |
Curr Med Res Opin |
2004 |
 |
Conference presentations
Titles / Authors |
Document type |
Read it |
ISPOR 18th Annual European Congress, Milan, 7-11 November 2015 |
Reduction of Complications and Associated Costs for Type 2 Diabetic Patients Using Continuous Subcutaneous Insulin Infusion In The UK (Roze S , Duteil E, Hallas N, de Portu S) |
Poster |
 |
Health-economic analysis of the use of sensor-augmented pump (SAP) therapy in the Netherlands compared to insulin pump therapy alone (CSII), in type 2 diabetic patients (Roze S , Duteil E, Hallas N, de Portu S) |
Poster |
 |
Contrasting model predicted life expectancy in patients with type 2 diabetes across diferrent mortality risk prediction models versus data from the Canadian chronic disease surveillance system (Foos V, Lamotte M, McEwan P) |
Poster |
 |
Validating approaches to modelling end-stage renal disease using the IMS Core Diabetes Model (Foos V, Lamotte M, McEwan P) |
Poster |
 |
EASD 51st annual meeting, Stockholm, 14-18 September 2015 |
Contrasting eight cardiovascular risk equations for use in type 2 diabetes cohorts using the CORE Diabetes Model (Lamotte M, Foos V, McEwan P) |
Abstract |
 |
ISPOR 20th Annual International Meeting , Philadelphia, 18-20 May 2015 |
Contrasting The Relative Risk Reduction Of Cardiovascular Events In The Core Diabetes Model Associated With Single Risk Factor Changes Across Alternative Risk Engines: Ukpds68, Ukpds82 And Swedish National Diabetes Registry Equations (Foos V, Lamotte M, McEwan P) |
Poster |
 |
Assessing the relative contribution to changes in quality adjusted life expectancy associated with HbA1c, weight and hypoglycaemia across multiple risk equations with the CORE Diabetes Model. (McEwan P, Evans M, Lamotte M, Foos V) |
Poster |
 |
Contrasting cost effectiveness results derived from contemporary sets of alternative risk equations in type 2 diabetes (Volker Foos, Mark Lamotte, Phil McEwan) |
Poster |
 |
Validating the ukpds 82 risk equations to contemporary outcomes studies in type 2 diabetes (Grant D, Foos V, McEwan P ) |
Poster |
 |
ISPOR 17th Annual European Congress, Amsterdam, 8-12 November 2014 |
Assessing the relationship between improved life expectancy due to better cardiovascular risk factor management and the likelihood of microvascular complications in type 2 diabetes mellitus (P. McEwan, D. Grant and V. Foos) |
Poster |
 |
Progression of Physiological Measurements Over Time in Type 1 Diabetes Mellitus Patients in France (A. Beaudet, R. Ong, A. Solomiac, N. Grandfils) |
Poster |
 |
Burden of Non-adherence to Type 1 Diabetes Mellitus Therapeutic Guidelines in France (A. Beaudet, R. Ong, X. Ansolabehere, P. Le Jeunne) |
Poster |
 |
All cause mortality validation of the IMS CORE diabetes model against predictions of the Charlson Comorbidity Index (V. Foos, P. McEwan, M. Lamotte and D. Grant) |
Poster |
 |
Impact of single risk factor changes on long term outcomes and cost in a type 2 diabetes modeling study contrasting projections with UKPDS 68 versus UKPDS 82 risk equations (V. Foos, P. McEwan and D. Grant) |
Poster |
 |
Quantifying nonlinear effects in stochastic Markov simulation using UKPDS 68 and UKPDS 82 equations in type 2 diabetes modeling analysis with the IMS CORE Diabetes Model (CDM) (P. McEwan, D. Grant, M. Lamotte and V. Foos) |
Poster |
 |
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Portugal (Troelsgaard A, Knudsen M, Maia-Lopes S, Luz M, Hemels M) |
Poster |
 |
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Slovakia (Troelsgaard A, Pitcher A, Binder R, Stetka R, Lovato E, Ondrusova M) |
Poster |
 |
The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulphonylurea in France (Troelsgaard A, Pitcher A, Lloyd A, Granados D, Hemels M) |
Poster |
 |
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic (Troelsgaard A, Pitcher A, Vesela S, Lovato E, Hemels M) |
Poster |
 |
ISPOR 19th Annual International Meeting, May 31- June 4, 2014, Montréal, Canada |
Comparing simulation run time requirements to achieve stabilized absolute and incremental costs effectiveness results in probabilistic vs. deterministic modeling analysis (V. Foos, P. McEwan and D. Grant) |
Poster |
 |
Contrasting cost effectiveness results derived from the UKPDS 68 and 82 risk equations in Type 2 diabetes (P. McEwan, V. Foos, and D. Grant) |
Poster |
 |
Illustrating the relationship between the number of hypoglycemic events, event rate reduction and the impact on estimates of quality of life improvement in health economic studies (V. Foos, P. McEwan and D. Grant) |
Poster |
 |
Validating the UKDS 82 risk equations to contemporary outcomes studies in type 2 diabetes (D. Grant, V. Foos and P. McEwan) |
Poster |
 |
Assessing simulation run time requirements to achieve stabilized absolute and incremental cost effectiveness results in type 2 diabetes: A study using the Core Diabetes model (Foos V, Grant D, McEwan P) |
Poster |
 |
The Cost-Effectiveness Evaluation of Canagliflozin Versus Dapagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy in Spain (Nielsen A, Pitcher A, Lovato E, Schubert A, Hemels M, Neslusan C, González B) |
Poster |
 |
ISPOR 16th Annual European Congress, 2-6 November 2013, Dublin, Ireland |
Assessing the significance of HbA1c durability in cost effectiveness analysis of 2nd line oral therapies in the management of type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant) |
Poster |
 |
Review of Cost of Diabetes Complications in Four European Countries. (A. Beaudet, E. Grabbi, F. Maurel, M. Ramos, A. Lebioda) |
Poster |
 |
Therapy escalation thresholds and the potential for biased cost effectiveness analysis when failing to sample baseline HbA1c in type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant) |
Poster |
 |
Correlating cost-effectiveness output with patient-level data input via the IMS CORE Diabetes Model (CDM). (P. McEwan, V. Foos, J. Palmer, M. Lamotte and D. Grant) |
Poster |
 |
The role of simulation modelling in planning long-term clinical trials in type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant) |
Poster |
 |
EASD 49th Annual Meeting, 23-27 September 2013, Barcelona, Spain |
Are we failing to capture the relationship between body mass index and cardiovascular disease and mortality in subjects with type 2 diabetes? (D. Grant, P. McEwan, V. Foos, J. Palmer and A. Lloyd) |
Poster |
 |
Defining the health economic value of avoiding weight gain and hypoglycaemia in type 2 diabetes Mellitus. (A. Lloyd, V. Foos, P. McEwan, D. Grant, M. Lamotte, J. Palmer) |
Poster |
 |
ADA 73rd Scientific Sessions, 21-25 June 2013, Chicago, IL, USA |
Do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type 2 diabetes? (P. McEwan, V. Foos, D. Grant, J. Palmer, M. Lamotte and A. Lloyd) |
Poster |
 |
Assessing the Consistency of Absolute Cardiovascular Risk Prediction and Relative Risk Reduction in Type 2 Diabetes Mellitus. (P. McEwan, M. Lamotte, D. Grant, J. Palmer, A. Lloyd and V. Foos) |
Poster |
 |
ISPOR 18th Annual International Meeting, 18-22 May, 2013 New Orleans, LA, USA |
Drivers of cost-effectiveness in type-2 diabetes mellitus. (McEwan P, Foos V, Grant D, Lamotte M, Palmer JL, Lloyd A) |
Podium presentation, Poster |
 |
Do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type-2 diabetes? (McEwan P, Foos V, Grant D, Palmer JL, Lamotte M, Lloyd A) |
Poster |
 |
Assessing the consistency of absolute cardiovascular risk prediction and relative risk reduction in type-2 diabetes mellitus. (McEwan P; Lamotte M; Grant D; Palmer JL; Lloyd A, Foos V) |
Poster |
 |
The cost and productivity consequences of non-severe hypoglycaemic episodes (nshe) in patients treated with sulfonylurea or dpp4 dual combination oral therapy. (Foos V, McEwan P, Grant D, Palmer JL, Lamotte M, Lloyd A) |
Poster |
 |
ISPOR 15th European Congress, 3-7 November 2012, Berlin, Germany |
Random number generators in Monte Carlo simulation. (McEwan P, Foos V, Chraibi M, Lloyd A, Palmer JL, Lamotte M, Grant D) |
Poster |
 |
Minimum run-time requirements to reduce Monte Carlo error in stochastic simulations. (Foos V, McEwan P, Lloyd A, Palmer JL, Lamotte M, Grant D) |
Poster |
 |
Systematic literature review of utility values associated with Type 2 Diabetes-related complications. (Beaudet A, Clegg JP, Lloyd A) |
Poster |
 |
48th EASD Annual Meeting, 1-5 October 2012, Berlin, Germany |
Assessing the relationship between the effect of glycemic control and avoided symptomatic hypoglycemia on quality of life in the management of type 2 diabetes. (Foos V, McEwan P, Lloyd A, Palmer JL, Lamotte M, Grant D) |
Poster |
 |
ISPOR 5th Asia-Pacific Conference, 2-4 September, 2012, Taipei, Taiwan |
Direct medical costs of Diabetes Mellitus in China: Annual cost of illness and long-term projections using a validated diabetes model. (Palmer JL, Caputo J, Foos V, Grant D, Lamotte M, Lloyd A, McEwan P) |
Poster |
 |
72nd Scientific Sessions, American Diabetes Association, 8-12 June, 2012, Philadelphia, PA |
Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. (Grant D, Foos V , Palmer J, Lloyd A, Evans M, Mcewan P) |
Poster |
 |
The Cost and Productivity Consequences of Non-Severe Hypoglycaemic Episodes (NSHE) in Patients Receiving Sulfonylurea or DPP4 Dual Combination Oral Therapy. (McEwan P, Evans M, Foos V, Lloyd A, Grant D) |
Poster |
 |
Validation and Evaluation of the Risk-To-Benefit Ratio of Glucose Lowering Therapies in High Cardiovascular Risk Type 2 Diabetes Patients; Projections using the IMS CORE Diabetes Model. (Foos V, Freemantle N, Palmer J, Grant D, Lloyd A, Evans M, Mcewan P) |
Oral presentation |
 |
Cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes (T2DM). (Fonda SJ, Graham C, Samyshkin Y, Munakata J, Powers J, Vigersky RA) |
Poster |
 |
The Mount Hood 2012 Challenge, 7-8 June, 2012, Baltimore Maryland, USA |
Minimum run-time requirements to reduce Monte Carlo error in stochastic simulations. (Volker Foos, Phil McEwan, Adam Lloyd, James Palmer, Mark Lamotte and David Grant) |
Oral presentation |
 |
ISPOR 17th Annual International Meeting. 2-6 June, 2012 Washington, DC, USA |
Long-term clinical and economic benefit associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a Core Diabetes Model study. (Lee WC, Samyshkin Y, Langer J, Palmer J) |
Poster |
 |
ISPOR 14th Annual European Congress, 5-8 November 2011, Madrid, Spain |
Projected cost-effectiveness of exenatide once weekly versus exenatide BID for the treatment of type 2 diabetes in the UK. (Wilson BP, Beaudet A, Caputo J, Timlin L) |
Poster |
 |
Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of type 2 diabetes in the UK. (Beaudet A, Wilson BP, Caputo J, Timlin L) |
Poster |
 |
Cost-effectiveness of transferring Type-2 Diabetic patients from Neutral Protamine Hagedorn (NPH) To Detemir in Portugal settings. (Carvalho D, Lindner L, Kozarzewski M) |
Poster |
 |
47th EASD Annual Meeting, 12-16 September 2011, Lisbon, Portugal |
Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta-analysis studies. (Foos V, Lloyd A, Freemantle N, Grant D, Herman W) |
Oral presentation |
 |
Estimating the impact of different methods of utility assessment on the value of interventions in Type 2 diabetes, Oral presentation. (Lloyd A, Foos V, Donatti C, Grant D, Herman W) |
Oral presentation |
 |
Duration of time off paid employment associated with diabetes-related complications. (Beaudet A, Myrén K-J, Grant D, Lloyd A) |
Poster |
 |
ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic |
Cost-effectiveness of Exenatide Versus Insulin Glargine and Versus Biphasic Insulin Aspart for the Treatment of Type 2 Diabetes in Portugal: A Long-term Health Economic Analysis. (Palmer JL, Pinto CG, Duarte R, Miguel LS, Gregor Z) |
Poster |
 |
Long-term clinical outcomes of Exenatide once-weekly versus Insulin Glargine for the treatment of Type 2 Diabetes projected using the Core Diabetes Model. (Timlin L, Beaudet A, Wilson B, Bruhn D, Boye KS, Palmer JL, Lloyd A) |
Poster |
 |
Long-Term cost-consequence analysis of Exenatide once weekly versus Sitagliptin or Pioglitazone in Type 2 Diabetes patients in the United States. (Aledort Gaebler J, Samyshkin Y, Guillermin ALG, Lloyd A) |
Poster |
 |
ISPOR 4th Asia-Pacific Conference, 5-7 September 2010, Hilton Phuket, Phuket, Thailand |
Clinical and cost effectiveness of biphasic insulin aspart 30 once or twice daily versus insulin glargine in type 2 diabetes mellitus: a modeling analysis in the Chinese setting. (Palmer JL, Beaudet A, White,J, Plun-Favreau J,Smith-Palmer J) |
Poster |
 |
70th Scientific Sessions Abstract Book, 2010 |
Starting an insulin therapy with glargine leads to lower long-term treatment costs compared to detemir in German type-2-diabetics: Results of a model approach. (Pfohl M, Dippel F-W, Reichelt A, Kostev K, Fuchs S, Kotowa W) |
Abstract |
 |
|